施维雅以25亿美元收购Day One,获得罕见肿瘤药物。
Servier to buy Day One for $2.5B, gaining rare oncology medicines
生物技术与制药领域的最新动态
Servier to buy Day One for $2.5B, gaining rare oncology medicines
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Post-Hoc Live: What will the US government do about China biotech?
Pfizer gets obesity drug approval in China shortly after buying local rights
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
FDA official questions need for advisory committees
Kura says its menin inhibitor is preferred treatment for some payers
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Roche, Element and Ultima push toward the $100 genome
FDA approves J&J's multiple myeloma combo as second-line treatment
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
New FDA bonus pilot to address 'workforce challenges'
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Tenaya wins support from Alnylam in cardio disease pact
Health AI dispatch from SF
China is taking on the world’s 10 most expensive medicines
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
How hospitals have shifted from experimenting with AI to justifying its cost
Yale’s Craig Crews builds model to guide biotech startups out of academia’s ‘valley of death’